Skip to content

Research of Diagnostic Value for BMJ Infants

Research of Diagnostic Value of Fecal miRNA and Intestinal Flora in Infants With BMJ

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04527536
Enrollment
300
Registered
2020-08-26
Start date
2020-10-01
Completion date
2022-09-30
Last updated
2020-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Jaundice, Neonatal

Brief summary

Breast milk jaundice (BMJ) is the main cause of neonatal hyperbilirubinemia. Excessive serum unconjugated bilirubin level will not only cause the interruption or early termination of breastfeeding, but also cause kernicterus. Which can cause long-term dysfunction in infants. But for a long time, BMJ diagnosis has relied on clinical exclusive methods, lack of objective and reliable laboratory indicators. Which leads to misdiag. This project is a single-center, prospective nested case-control study. It is planned to establish a neonatal BMJ cohort. According to the admission criteria, 100 cases of early-onset BMJ and late-onset BMJ will be completed, and 100 healthy controls collected during the same period. , Compare the detection results of fecal miRNA and intestinal flora of the two groups of BMJ children and healthy controls, draw the ROC curve of the joint diagnosis, conduct research on the combined diagnostic value of fecal miRNA and intestinal flora analysis, and try to find the feasibility and practical value of diagnostic markers for feces in infants with BMJ.

Detailed description

This project is a single-center, prospective nested case-control study to investigate feasibility and practical value of diagnostic markers in infants with BMJ. According to the admission criteria, 100 cases of early-onset BMJ, 100 late-onset BMJ and 100 healthy controls will be selected. Their feces, peripheral venous blood and mothers' breast milk were collected for further testing. Compare the detection results of fecal miRNA and intestinal flora of the two groups of BMJ children and healthy controls, draw the ROC curve of the joint diagnosis, conduct research on the combined diagnostic value of fecal miRNA and intestinal flora analysis. This study is to find the objective and reliable laboratory indicators to diagnose BMJ.

Interventions

DIAGNOSTIC_TESTNeonatal hyperbilirubinemia

Neonatal hyperbilirubinemia:The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.

Sponsors

Shanghai First Maternity and Infant Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
4 Days to 42 Days

Inclusion criteria

* All the following conditions must be met 1. Term newborns admitted to hospital with neonatal hyperbilirubinemia 2. Exclusive breastfeeding or mainly breastfeeding 3. Exclude perinatal infection, G-6P-D deficiency, homoimmune hemolysis, polycythemia, scalp hematoma, intracranial hemorrhage, cholestasis, hypoglycemia, hypothyroidism, hypothermia, neonatal asphyxia, fetus Pathological jaundice factors such as delayed stool excretion.

Exclusion criteria

* As long as any one of the following conditions should be excluded 1. During the follow-up period, breastfeeding was terminated or the daily milk powder intake exceeded 200 ml. 2. Other pathological jaundice was diagnosed during the follow-up period. 3. Take probiotics during the sampling period. 4. The guardian asked to withdraw from the study halfway.

Design outcomes

Primary

MeasureTime frameDescription
Analysis of newborn feces miRNA and intestinal flora analysis2021.10.01-2022.09.30Analysis of newborn feces miRNA and intestinal flora analysis
UGT1A1 test in newborn blood2021.10.01-2022.09.30UGT1A1 test in newborn blood
Analysis of breast milk exosomes miRNA2021.10.01-2022.09.30Analysis of breast milk exosomes miRNA

Contacts

Primary ContactJing Li, Doctorate
zzhlq3@qq.com01861358683669

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026